Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

26.1%

85 terminated/withdrawn out of 326 trials

Success Rate

67.9%

-18.6% vs industry average

Late-Stage Pipeline

6 trials in Phase 3/4

Results Transparency

71%

128 of 180 completed trials have results

Key Signals

39 recruiting128 with results65 terminated20 withdrawn

Enrollment Performance

Analytics

Phase 2

138(48.4%)

N/A

72(25.3%)

Phase 1

58(20.4%)

Early Phase 1

11(3.9%)

Phase 3

3(1.1%)

Phase 4

3(1.1%)

285Total

Phase 2(138)

N/A(72)

Phase 1(58)

Early Phase 1(11)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (326)

Showing 20 of 326 trials

NCT07737769Phase 1Not Yet Recruiting

Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome

Role: lead

NCT06580054Phase 2Active Not Recruiting

Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma

Role: lead

NCT05911269Not ApplicableCompleted

Feasibility of Virtual, Tailored, Music-Based Relaxation for Anxiety in Adolescent and Young Adult Cancer Survivors

Role: lead

NCT04140162Phase 2Active Not Recruiting

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

Role: lead

NCT07096999Recruiting

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

Role: lead

NCT06784336Phase 2Recruiting

Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation

Role: lead

NCT01750567Phase 2Completed

A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL

Role: lead

NCT07673614Not ApplicableNot Yet Recruiting

Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors

Role: lead

NCT06356155Phase 2Recruiting

Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer

Role: lead

NCT06941324Not ApplicableRecruiting

Solution-Focused Brief Therapy for Support of Psychological Distress in Adolescent and Young Adult Cancer Survivors

Role: lead

NCT07532525Phase 1Recruiting

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

Role: lead

NCT05996107Phase 1Recruiting

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

Role: lead

NCT04748042Phase 2Active Not Recruiting

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Role: lead

NCT03781986Phase 1Active Not Recruiting

APG-115 in Salivary Gland Cancer Trial

Role: lead

NCT07630155Not ApplicableRecruiting

Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma

Role: lead

NCT07682649Phase 1Not Yet Recruiting

Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Role: lead

NCT04925089Recruiting

Localized Leiomyosarcoma Biomarker Protocol